DAMOCLES Diagnostics
Entity

  • DAMOCLES Diagnostics

    Created in 2023
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    53

  • Activities

    healthtech

  • Technologies

    SaaS

  • Entity types

    Startup

  • Location

    87000 Limoges, France

    Limoges

    France

  • Employees

    Scale: 2-10

    Estimated: 6

  • Engaged corporates

    2
    2 0

  • Added in Motherbase

    8 months, 1 week ago
Description
  • Value proposition

    Biophysical monitoring for One Health

    DAMOCLES Diagnostics is a deeptech start-up founded in 2023 in Limoges. It develops an innovative technology that allows the measurement of the biophysical properties of a microorganism in a few minutes, without labeling and respecting the living. The first targeted application is the antibiotic sensitivity test (AST) which is very fast and automated.

    The innovation is based on the transformation of a proven technology in oncology, adapted to medical microbiology laboratories, both in human and animal health. The DAMAST system includes a machine, a diagnostic software and kits for a wide range of applications in microbiology.

    DAMOCLES Diagnostics has validated its DAMAST system on more than 500 bacteria/antibiotic combinations, with performances in accordance with CE-IVD regulations. A second internal clinical study is underway on another panel of bacterial species and antibiotics.

    Our team is composed of 8 people with transdisciplinary skills. We are supported by the INSERM U1092 RESINFIT and U1308 CAPTUR laboratories, which gives us privileged access to cutting-edge technical platforms.

    Having received many expressions of interest from future customers (private laboratories and hospitals), we aim for the industrialization of the DAMAST system in 2025, followed by the launch of a clinical trial in 2026.

    Antibiotics, AST, CE IVD, IVD, AMR, One Health, MedTech, and Deeptech

  • Original language

    Révolutionnons l'antibiogramme en 2 heures : des résultats rapides, des vies préservées, une antibiorésistance combattue

    DAMOCLES Diagnostics est une start-up deeptech fondée en 2023 à Limoges. Elle développe une plateforme innovante, DAMAST, qui permet de réaliser des antibiogrammes rapides en seulement 2 heures, contre 12 à 24 heures pour les méthodes conventionnelles actuelles. Le système comprend, en plus de l’automate DAMAST, un logiciel de diagnostic et d’analyse automatisée des données, ainsi que des kits permettant une large gamme d'applications en microbiologie, à la fois en santé humaine (sepsis, infections urinaires) et animale.

    Notre équipe est composée de 6 personnes aux compétences transdisciplinaires. Nous sommes soutenus par les laboratoires INSERM U1092 RESINFIT et U1308 CAPTUR, ce qui nous permet d'avoir un accès privilégié à des plateaux techniques de pointe.

    Ayant reçu de nombreuses manifestations d'intérêt de la part de futurs clients (laboratoires privés et hôpitaux), nous visons l'industrialisation du système DAMAST en médecine vétérinaire 2025, puis le lancement d'un essai clinique en santé humaine en 2026.

Corporate interactions BETA
Corporate TypeTweets Articles
AQUITI Gestion
AQUITI Gestion
Startup accelerator & VC, Venture Capital and Private Equity Principals
AQUITI Gestion
Startup accelerator & VC, Venture Capital and Private Equity Principals 		Other

23 Jul 2023


French Tech Limousin
French Tech Limousin
French Tech, IT Services and IT Consulting
French Tech Limousin
French Tech, IT Services and IT Consulting 		Other

29 Jun 2023


Similar entities
Last news
Show all articles
Social network dynamics